Mar 31, 2020
Lannett Begins Marketing Generic Adderall® XR
Feb 13, 2020
FDA In Brief: FDA Requests Voluntary Withdrawal of Weight-Loss Medication After Clinical Trial Shows an Increased Occurrence of Cancer
Feb 13, 2020
Eisai to Voluntarily Withdraw BELVIQ®/BELVIQ XR® in the U.S.
Dec 12, 2019
Lannett To Commence Marketing Generic Adderall® XR
Dec 09, 2019
Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program
Oct 30, 2019
Research Forum to Highlight Novel Anti-obesity Medications Media Availability on Nov. 4, 2019, at 12:30 p.m. (PST)
Oct 29, 2019
At Paris' Orly airport, a daily duel between customs and Guiana drug mules
Sep 30, 2019
Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study
Sep 27, 2019
Currax(TM) Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc.
Aug 21, 2019
Kenyan who swallowed 68 cocaine packets arrested in Thailand
Jul 16, 2019
Operation Toupee: man arrested in Spain with cocaine under wig
Jun 24, 2019
Global Eating Disorders Markets, 2017-2018 & 2019-2026: Edgemont's Fluoxetine Tablets and Takeda's Vyvanse are the Only FDA-Approved Drugs
Jun 18, 2019
Global Anti-Obesity Drugs Market Outlook to 2024: Online Drug Stores Boost Sales
Feb 25, 2019
FDA Accepts Eisai's Supplemental New Drug Application (sNDA) to Update the Labeling for Anti-Obesity Agent BELVIQ® (lorcaserin HCl)
Dec 19, 2018
Workforce Drug Positivity Rises by Double-Digits in Almost One-Third of U.S. Industry Sectors Examined, According to New Quest Diagnostics Analysis
Nov 08, 2018
White House ONDCP Deputy Director James Carroll to Address Attendees at Healthcare Made Practical's Inaugural National Cocaine, Meth, & Stimulant Summit
May 02, 2018
KVK Tech, Inc. Announces 1-2-3 Savings Program for Lomaira(TM) (phentermine hydrochloride USP) 8 mg Tablets, CIV
Apr 23, 2018
Peptron Expands Exclusive License with NIH to Support Developing SR-exenatide to Treat Neurodegenerative Diseases
Mar 12, 2018
Orexigen Therapeutics, Inc. Plans For Near-term Sale Using Structured Process Through Chapter 11 Of U.S. Bankruptcy Code
Feb 01, 2018
Global Anti-Obesity Drugs Market 2017-2023: Market is Estimated to Witness a CAGR of 20.9% - Key Players are F. Hoffmann La Roche, GSK, Orexigen Therapeutics, Vivus Therapeutics, and Eisai